Quantus

Komipharm International

A041960 · KOSDAQ
₩7,290+7.21%
2026-08-03 close

Komipharm International — pricey right now, or cheap? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p

Beat the market on 62.1% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock flashed this signal 2 times over the last ~2 years (see the signal history below for each date).

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 295 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Valuation in its own history

PER 41 · PBR 8.63 — own history (2001-10~) percentiles 95/100 · 67/100

PER95/100
PBR67/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 1.80
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
1.80
Beneish M-Score
-2.15

No statistical flag

Sloan accrual
3.48%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 성장 + 마진 확대 + FCF 양수

Positive

매출이 +37.8% 성장하면서 영업이익률이 -14.9%에서 8.4%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.

Evidence

매출 YoY +37.8%영업이익률 -14.9%→8.4%FCF 12,825

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

8/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score8/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업외손익 급변 (영업이익 대비 116% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 160 of 290, share 0.1%.

160 / 2900.1%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6코미팜0.1%

Concentration

DistributedCR3 16.6%
HHI 201290 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
14
Median P/B
1.47
Level
넓음
n
269

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
8.4%
Interest coverage
1.5x
Return on equity (ROE)
21.1%

Operating margin −5pp

Interest coverage risk
Interest coverageBase 1.5x adverse case 0.6x
Return on equity (ROE)Base 21.1% adverse case -1.9%

Revenue −15%

Interest coverage risk
Interest coverageBase 1.5x adverse case 1.3x
Return on equity (ROE)Base 21.1% adverse case 1.6%

Interest rate +2pp

Interest coverage risk
Interest coverageBase 1.5x adverse case 1.1x
Return on equity (ROE)Base 21.1% adverse case 0.9%

Interest coverage limit

Current margin 3pp

Interest coverage limit at an operating margin of 5.5%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-18

Suppliers disclosed by the company in its 2026-03-18 annual report.

Purchase amount

KRW 100m
  1. Amoxicillin
    KRW 386.6T
  2. Trihydrate
    KRW 386.6T
  3. Egg
    KRW 249.5T
  4. Bovine
    KRW 130.1T
  5. Fetal
    KRW 130.1T
  6. Serum
    KRW 130.1T

Suppliers without disclosed amount

FootMouthDiseaseBulkRoller

Financials at a glance

Komipharm International's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 양경훈39.94%2024-10-02 · 증감 -0.02%p

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

Recent filings

Komipharm International's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

Strong buy (52w high + volume)×2
26-04-17-24.4%26-03-25-3.1%
New MA alignment×4
26-04-24-24.8%26-04-15-8.9%26-03-27+11.3%26-03-25-3.1%

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy